<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117604">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01827969</url>
  </required_header>
  <id_info>
    <org_study_id>IB2009-58</org_study_id>
    <nct_id>NCT01827969</nct_id>
  </id_info>
  <brief_title>Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy</brief_title>
  <acronym>USF</acronym>
  <official_title>Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Bergonié</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The treatment consists of tumor ablation by Ablathermy Focused Ultrasound  (USF), guided by
      MRI, performed under local anesthesia and sedation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment consists of tumor ablation by USF, guided by MRI, performed under local
      anesthesia and sedation. Patients will be operated (mastectomy) from 48 hours after
      ablation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment difficulties
  </why_stopped>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Evaluate the effectiveness of ablathermy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the effectiveness of ablathermy focused ultrasound breast tumors on histological criteria in terms of destruction of the tumor mass by coagulation necrosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Assessment of apoptotic phenomena in the margins of lesions treated</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of apoptotic phenomena in the margins of lesions treated
Know the immediate complications focused ultrasound
Assess the pain experienced by patients during the procedure performed under sedation.
Check the real-time processing by mapping temperature measured by MRI and correlate these mappings to the histological findings</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Tumor</condition>
  <arm_group>
    <arm_group_label>ablathermy focused ultrasound</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ablathermy focused ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ablathermy focused ultrasound</intervention_name>
    <description>ablathermy focused ultrasound</description>
    <arm_group_label>ablathermy focused ultrasound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Invasive Breast Carcinoma with histologically confirmed hormone receptor analysis,
             the grade of the tumor, the expression of Her-2.

          -  Lesion classified T1-T2-T3 unifocal or multifocal with or without associated
             microcalcifications

          -  Lesion recognizable and identifiable in MRI

          -  Indication of mastectomy with or without axillary

          -  Lesion located more than 10 mm from the skin, the nipple and pectoralis major

          -  No cons-indication to MRI (pacemaker)

          -  Women whose age is ≥ 18 years

          -  If premenopausal patient: patient contraceptives

          -  Patient has signed informed consent

          -  Affiliation to a social security scheme

        Exclusion Criteria:

          -  Tumor-TD T4B classified or non-palpable lesion

          -  If age &lt;70 years: no indication of adjuvant chemotherapy and neoadjuvant

          -  MRI lesions have not been identified, located within 10 mm of the skin and pectoral
             muscle, greater than 25 mm diameter

          -  Inability to hold still in the prone position, arms extended, for 30 minutes

          -  Contraindication to MRI

          -  Patient deprived of liberty and major subject of a measure of legal protection or
             unable to consent

          -  Patient participating in another interventional clinical trial within 30 days prior
             to baseline and during the trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PALUSSIERE Jean, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <state>Aquitaine</state>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.bergonie.org/fr/essais-clinique.html</url>
    <description>Site internet du promoteur, l'Institut Bergonié</description>
  </link>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 9, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>breast tumor</keyword>
  <keyword>planned mastectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
